Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia
Status:
Completed
Trial end date:
2019-08-28
Target enrollment:
Participant gender:
Summary
A clinical study to evaluate the efficacy of a drug called eltrombopag in adult patients
affected of primary immune thrombocytopenia as first treatment to address the disease.